{"schema_version":"secwatch.filing_event.v1","accession":"0001022079-22-000157","form_type":"8-K","ticker":"DGX","cik":"0001022079","company_name":"QUEST DIAGNOSTICS INC","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.263778+00:00","generated_at":"2026-06-21T15:35:24.015867+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Quest Diagnostics appoints four executive officers to severance plan; amends by-laws","bullets":["Four executives appointed as executive officers and Schedule B participants in severance plan: Mark Delaney, Mark Gardner, Karthik Kuppusamy, Patrick Plewman (effective Nov 16, 2022).","Board amended by-laws on Nov 14, 2022 regarding director nominations, proxy solicitations, and compliance with Rule 14a-19.","Schedule B participants receive 1x salary + 1x bonus pre-CIC; 2x salary + bonus post-CIC, plus benefits.","By-law amendments are ministerial, clarifying, and conforming changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001022079-22-000157","json":"https://secwatch.observer/filing/0001022079-22-000157.json","markdown":"https://secwatch.observer/filing/0001022079-22-000157.md","text":"https://secwatch.observer/filing/0001022079-22-000157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/dgx-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:35:24.015867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"545fca1a3c","claim":"Patrick T. Plewman was appointed as Senior Vice President for Diagnostic Services at QUEST DIAGNOSTICS INC.","evidence_excerpt":"On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the \"Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the \"Plan\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President for Diagnostic Services"}],"fact_type":"executive_change"},{"claim_id":"63d38f0e75","claim":"Karthik Kuppusamy was appointed as Senior Vice President, Clinical Solutions at QUEST DIAGNOSTICS INC.","evidence_excerpt":"On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the \"Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the \"Plan\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Clinical Solutions"}],"fact_type":"executive_change"},{"claim_id":"9ec7877775","claim":"Mark E. Delaney was appointed as Senior Vice President and Chief Commercial Officer at QUEST DIAGNOSTICS INC.","evidence_excerpt":"On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the \"Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the \"Plan\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President and Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"ec84e6f496","claim":"Mark A. Gardner was appointed as Senior Vice President, Molecular Genomics and Oncology at QUEST DIAGNOSTICS INC.","evidence_excerpt":"On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the \"Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the \"Plan\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Molecular Genomics and Oncology"}],"fact_type":"executive_change"},{"claim_id":"5b6f4a7ea131191f1878dedd312b9ced2d961d99","claim":"QUEST DIAGNOSTICS INC: Amended and restated By-Laws to revise Sections 1.05, 1.06 and 1.07 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-14).","evidence_excerpt":"On November 14, 2022, the Board of Directors (the “Board”) of the Company amended and restated the Company's By-Laws (the \"By-Laws\"). The amendments (a) revise Sections 1.05, 1.06 and 1.07 with respect to nominations of directors and solicitations of proxies, including compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207922000157/0001022079-22-000157-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-11-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}